- Home
- CYRX vs GOSS Comparison
CYRX vs GOSS Comparison
Compare CYRX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- GOSS
- Stock Information
- Founded
- CYRX 1999
- GOSS 2015
- Country
- CYRX United States
- GOSS United States
- Employees
- CYRX N/A
- GOSS N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- GOSS Health Care
- Exchange
- CYRX Nasdaq
- GOSS Nasdaq
- Market Cap
- CYRX 438.7M
- GOSS 501.2M
- IPO Year
- CYRX N/A
- GOSS 2019
- Fundamental
- Price
- CYRX $9.24
- GOSS $2.45
- Analyst Decision
- CYRX Strong Buy
- GOSS Strong Buy
- Analyst Count
- CYRX 9
- GOSS 6
- Target Price
- CYRX $12.56
- GOSS $8.60
- AVG Volume (30 Days)
- CYRX 762.8K
- GOSS 3.1M
- Earning Date
- CYRX 11-04-2025
- GOSS 11-03-2025
- Dividend Yield
- CYRX N/A
- GOSS N/A
- EPS Growth
- CYRX N/A
- GOSS N/A
- EPS
- CYRX 1.35
- GOSS N/A
- Revenue
- CYRX $237,879,000.00
- GOSS $40,237,000.00
- Revenue This Year
- CYRX N/A
- GOSS N/A
- Revenue Next Year
- CYRX $9.20
- GOSS $16.11
- P/E Ratio
- CYRX $6.87
- GOSS N/A
- Revenue Growth
- CYRX 24.93
- GOSS N/A
- 52 Week Low
- CYRX $4.58
- GOSS $0.66
- 52 Week High
- CYRX $11.44
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- CYRX 45.23
- GOSS 50.55
- Support Level
- CYRX $8.95
- GOSS $2.28
- Resistance Level
- CYRX $11.11
- GOSS $2.53
- Average True Range (ATR)
- CYRX 0.73
- GOSS 0.15
- MACD
- CYRX -0.17
- GOSS 0.03
- Stochastic Oscillator
- CYRX 13.88
- GOSS 81.40
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.